*Review* **Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects**

**Mousa A. Alghuthaymi <sup>1</sup> , Atef A. Hassan <sup>2</sup> , Anu Kalia 3,\* , Rasha M. H. Sayed El Ahl <sup>2</sup> , Ahmed A. M. El Hamaky <sup>2</sup> , Patrik Oleksak <sup>4</sup> , Kamil Kuca 4,\* and Kamel A. Abd-Elsalam 5,\***


**Abstract:** The global recognition for the potential of nanoproducts and processes in human biomedicine has given impetus for the development of novel strategies for rapid, reliable, and proficient diagnosis, prevention, and control of animal diseases. Nanomaterials exhibit significant antifungal and antimycotoxin activities against mycosis and mycotoxicosis disorders in animals, as evidenced through reports published over the recent decade and more. These nanoantifungals can be potentially utilized for the development of a variety of products of pharmaceutical and biomedical significance including the nano-scale vaccines, adjuvants, anticancer and gene therapy systems, farm disinfectants, animal husbandry, and nutritional products. This review will provide details on the therapeutic and preventative aspects of nanoantifungals against diverse fungal and mycotoxin-related diseases in animals. The predominant mechanisms of action of these nanoantifungals and their potential as antifungal and cytotoxicity-causing agents will also be illustrated. Also, the other theragnostic applications of nanoantifungals in veterinary medicine will be identified.

**Keywords:** nanoantifungal; mycotoxin degradation; theragnostic; veterinary
